滚动资讯
FierceBiotechOryon shines out of stealth with $21M to fight Parkinson's diseaseFierceBiotechPfizer, Valneva blame low Lyme cases for phase 3 vaccine fail but still plan approval pushIlluminaCanaccord reiterates Hold on Illumina stock amid Roche competition - Investing.com10x Genomics BlogThese Are the Only 3 Stocks That Cathie Wood Bought Last Week - The Motley FoolEndpoints NewsApogee shares positive mid-stage maintenance data for eczema drug that could challenge Dupixent, EbglyssEndpoints NewsArikayce could become Insmed’s second blockbuster following late-stage win in lung infectionEndpoints NewsSanofi extends $180M to California T cell engager startup KaliEndpoints NewsPfizer's Lyme disease vaccine trial hampered by lack of casesIlluminaNordea Investment Management AB Boosts Stake in Illumina - National TodayBioPharma DiveRisk, readiness and resilienceIllumina因Grail剥离延迟及生物科技板块逆风，Illumina公司股票再受审视——特别报道Agilent安捷伦科技推进色谱创新，助力2026年制药与生物技术效率提升——特别报道
Endpoints News 2026年1月14日

#JPM26：专访百时美施贵宝CEO克里斯·博纳，展望2026年发展前景

#JPM26：专访百时美施贵宝CEO克里斯·博纳，展望2026年发展前景

原文
暂时没有全文，请查看原始来源。

目录

59 全部